NEW YORK — Artificial intelligence startup Anthropic saw its shares slide to around $85 on Friday afternoon following a massive Nasdaq public listing that initially valued the company at more than $1 trillion, according to news reports. The San Francisco-based maker of the Claude chatbot had priced its initial public offering at $83 per share on Wednesday before opening trading on Thursday significantly higher at $111.50, ABC News reported.
The record-breaking offering surpassed the previous benchmark set by SpaceX over the summer, Fortune reported. On Friday, Anthropic revealed that underwriters purchased additional shares, pushing the total capital raised to roughly $93.5 billion, according to Fortune. Despite a broader retreat in technology equities that pulled the stock down from its opening day close of over $97 per share, the firm maintained a market value of approximately $1.1 trillion, exceeding retail giant Walmart in valuation, Fortune reported.
Windfalls for Founders and Tech Giants
The debut generated immense paper wealth for Anthropic’s leadership and corporate investors. Co-founders Dario Amodei, who serves as chief executive officer, and his sister Daniela Amodei, the company’s president and board chair, entered multi-billionaire status alongside five other co-founders, ABC News reported. Each of the seven co-founders retains between 237 million and 241 million shares, rendering their individual stakes worth roughly $20 billion at Friday’s share price, according to Fortune.
The seven co-founders also sold about 3.38 million shares each during the initial offering, yielding roughly $280 million apiece, Fortune reported. Anthropic’s IPO filing shows that the founding group retains majority control over the firm with 50.1 percent of shareholder voting power. According to the company’s regulatory filings, the co-founders have voluntarily pledged 80 percent of their personal equity to philanthropic causes, though the commitments are non-binding, Fortune reported.
However, the largest financial gains belong to corporate backers Amazon and Google. Anthropic’s filings indicate Amazon owns 14.6 percent of outstanding shares while Google holds 13.4 percent, Fortune reported. At Friday’s valuation, Amazon’s stake was worth approximately $165 billion, while Google’s position stood at about $151 billion, according to Fortune.
Future Growth and Commercial Expansion
Following its market debut, Anthropic faces pressure to demonstrate long-term profitability and sustainable commercial growth. In its public prospectus, the firm highlighted life sciences and medical research as major operational targets, asserting that artificial intelligence could accelerate discoveries to address diseases such as cancer and Alzheimer’s, CBS News reported.
Dario Amodei previously stated in an August social media post that he believes AI could make it possible to cure most human diseases within five to 10 years, CBS News reported. The company operates a biology wet lab in San Francisco and has partnered with pharmaceutical companies, including Eli Lilly and Co., to integrate its Claude models into scientific research pipelines, according to CBS News.
Industry analysts noted that while coding and cybersecurity remain proven revenue streams, expanding into biopharmaceuticals offers lucrative opportunities. Morningstar senior equity analyst Malik Ahmed Khan told CBS News that even minor efficiency gains in drug development hold immense financial value for commercial partners.
“If you improve your drug’s efficiency by a couple of percentage points, that can make a world of difference,” Khan told CBS News.
Safety Concerns and Market Outlook
Anthropic’s public debut arrives alongside heightened scrutiny surrounding the safety and development pace of frontier AI models. Dario Amodei has publicly highlighted severe risks associated with advanced AI systems while simultaneously advocating for their potential benefits, ABC News reported. In September, Amodei announced a precautionary slowdown in model development to focus on risk mitigation, a move mirrored by competitor OpenAI, according to ABC News.
What remains to be seen is how Anthropic will convert its life sciences research into consistent revenue while navigating stock lockup expirations for its 5,300 employees. Under current rules, non-founder staff may sell up to 10 percent of designated holdings, with additional equity unlocking after the publication of the company’s 2026 financial results, Fortune reported.



